Keywords: Pfizer, Tafamidis, TTR-FAP, FDA, USA, Advisory committee, Vyndaqel

FDA advisory panel gives mixed views on Pfizer's tafamidis

Article | 25 May 2012

• Print This

The US Food and Drug Administration's peripheral and Central Nervous System Drugs Advisory Committee yesterday voted on pharma behemoth Pfizer's ( ...

Enjoying this article? To continue reading you need to login or subscribe.